Davis will lead comms for AstraZeneca

Share this article:
AstraZeneca named the AARP's Lisa Davis, a long-time Washington communications hand, to head all internal and external corporate communications in the US.

Davis, who becomes VP, corporate communications, a new position, heads a team of 30 and reports to David Nicoli, VP corporate affairs. She was head of PR and communications for AARP, where she worked with healthcare PR pioneer Bill Novelli, founder of Porter Novelli and current AARP CEO. She was national deputy press secretary for President Clinton's re-election campaign in 1996, and from 1993-1996, she served as press secretary for the Democratic Leadership Council and the Progressive Policy Institute.

Davis will head implementation of a corporate reputation campaign for the firm. "AstraZeneca has a great story to tell, and we want to be able to tell that to a broader audience," she said. "People know a lot about our products but they know a lot less about the company." Edelman, will assist on the campaign.

"We have an industry that is, by nature, a white hat industry," she said. "Our scientists get up every day and try to figure out how to help someone's health problem. That's a noble goal, and somewhere along the way, people stopped knowing that."

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.